Drug Profile
Memantine - Cerecor
Alternative Names: FP-01 - Cerecor; FP01 lozenges; memantine lozengesLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Johns Hopkins University School of Medicine
- Developer Cerecor
- Class Amines; Analgesics; Antidementias; Antiglaucomas; Antiparkinsonians; Antispastics; Antitussives; Eye disorder therapies; Nitrates; Nootropics; Organic bridged compounds; Small molecules; Vascular disorder therapies
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cough
Most Recent Events
- 16 Sep 2015 No recent reports on development identified - Phase-II for Cough in USA, Chile and Peru (PO)
- 12 Sep 2013 Cerecor completes a phase IIb trial in Cough in USA (NCT01703923)
- 10 Jul 2013 Cerecor completes enrolment in its phase IIb trial for Cough in USA (NCT01703923)